New cancer drug combo enters key testing phase

NCT ID NCT04557449

Ongoing Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug, PF-07220060, to see if it is safe and can help control advanced cancers. It will be given alone and in combination with other standard hormone therapies. The trial is for people with certain advanced solid tumors, including breast, prostate, and lung cancers, who have run out of other effective treatment options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Brigham & Women's Hospital

Boston, Massachusetts, 02115, United States
COI Centro Oncologico Internacional S.A.P.I. de C.V.

Mexico City, Mexico City, Mexico
Cancer Hospital Chinese Academy of Medical Science

Beijing, Beijing Municipality, 100021, China
Cancer Research UK Edinburgh Centre

Edinburgh, Edinburgh, CITY of, EH4 2XR, United Kingdom
Clínica Universitaria Reina Fabiola

Córdoba, X50004FHP, Argentina
Dana Farber Cancer Institute- Chestnut Hill

Newton, Massachusetts, 02459, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Ellison Institute

Los Angeles, California, 90064, United States
Fakultna nemocnica s poliklinikou Nove Zamky

Nové Zámky, 940 34, Slovakia
Fakultni nemocnice Olomouc

Olomouc, 779 00, Czechia
Fundación CORI para la Investigación y Prevención del Cáncer

La Rioja, F5300COE, Argentina
Fundación Cenit Para La Investigación En Neurociencias

CABA, Ciudad Autã³noma de Buenos Aires, 1125, Argentina
Fundación Respirar

Buenos Aires, C1426ABP, Argentina
Henan Cancer Hospital

Zhengzhou, Henan, 450008, China
Hospital Británico de Buenos Aires

Ciudad Autónoma de Buenos Aires, Buenos Aires, 1280, Argentina
Hospital MAC Periferico Sur

Mexico City, Mexico City, 04700, Mexico
Hospital Reforma

Oaxaca City, Oaxaca, 68000, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

Monterrey, Nuevo León, 64460, Mexico
Hubei Cancer Hospital

Wuhan, Hubei, 430079, China
INCAN

Mexico City, Mexico City, 14080, Mexico
Narodny onkologicky ustav

Bratislava, 833 10, Slovakia
National Cancer Center Hospital East

Kashiwa, Chiba, 277-8577, Japan
Oaxaca Site Management Organization

Oaxaca City, 68000, Mexico
Onkologicky ustav sv. Alzbety, s.r.o., Interna klinika VSZaSP a OUSA

Bratislava, 812 50, Slovakia
POKO Poprad, s.r.o.

Poprad, 058 01, Slovakia
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
Sarah Cannon Research Institute - Pharmacy

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute UK

London, W1G 6AD, United Kingdom
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310016, China
Smilow Cancer Hospital Phase 1 Unit

New Haven, Connecticut, 06511, United States
Smilow Cancer Hospital at Yale - New Haven

New Haven, Connecticut, 06510, United States
St Bartholomew's Hospital

London, London, CITY of, EC1A 7BE, United Kingdom
The Christie Hospital NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
The First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, 710061, China
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Vseobecna fakultni nemocnice v Praze

Prague, 12808, Czechia
Yale-New Haven Hospital-Yale Cancer Center

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

ADENOCARCINOMA OF LUNG BREAST NEOPLASMS LIPOSARCOMA PROSTATE CANCER